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CD44 is a marker of tumour-initiating cells and is upregulated in invasive breast carcinoma; however, its role in the cancer progression
is unknown. Here, we show that antibody-mediated CD44-targeting in human breast cancer xenografts (HBCx) significantly reduces
tumour growth and that this effect is associated to induction of growth-inhibiting factors. Moreover, treatment with this antibody
prevents tumour relapse after chemotherapy-induced remission in a basal-like HBCx.
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Breast cancer remains a leading cause of morbidity and mortality in
women. The long-term survival of patients with advanced breast
cancers is still poor despite recent therapeutic improvements
(Kamangar et al, 2006). The main reasons for the poor clinical
outcomes are the local and distant tumour recurrences. New targets
are therefore needed to improve successful treatments. The CD44
glycoprotein is highly expressed in breast tumours and this
overexpression has been described as a poor prognostic factor
(Gotte and Yip, 2006). CD44 is involved in several processes,
including tumour cell proliferation, adhesion and invasion (Ponta
et al, 2003). Interestingly, CD44 was also found to be a positive
marker of tumour-initiating cells in different types of tumours,
including breast cancers (Al-Hajj et al, 2003). In vivo CD44
targeting by siRNA and by specific antibody results in anti-tumor
activity in colon cancer xenografts and human acute leukaemia
xenografts, respectively (Jin et al, 2006; Subramaniam et al, 2007).
In breast cancer, the role of CD44 in cell proliferation is still
unclear. To determine if CD44 targeting could affect tumour growth
in vivo, we used the P245 monoclonal antibody against the CD44
cell surface receptor that was earlier shown to inhibit the
development of human leukaemia xenografts (Jin et al, 2006).
MATERIALS AND METHODS
Mice, compounds, treatment and tumour growth
measurement
Female Swiss nude mice, 10-week old, were purchased from
Charles River (Les Arbresles, France) and maintained in specific
pathogen-free conditions. Their care and housing were in
accordance with institutional guidelines as put forth by the French
Ethical Committee (Agreement B75-05–18, France) under the
supervision of an authorised investigator (MF Poupon).
The murine anti-CD44 monoclonal antibody (P245) and Hermes3
were supplied by Laurence Boumsell (INSERM, Paris, France) and
David Naor, respectively, and the isotype control (IgG1) was from
Sigma-Aldrich (St Louis, MO, USA). Adriamycin (Doxorubicin)
and cyclophosphamide (Endoxan) were purchased from Teva
Pharmaceuticals (Paris, France) and Baxter (Maurepas, France),
respectively. Adriamycin and cyclophosphamide combination was
designated as AC. Hyaluronan (HA, MW: 5 10
4 to 2 10
6Da) was
provided by Javenech Cie (Fouge `res, France).
Human breast cancer xenografts, HBCx-3, -8 and -10, were
established as detailed (Marangoni et al, 2007). Treatments were
done on groups of eight animals (HBCx-3 and HBCx-8) and 12
animals for the tumour recurrence experiment (HBCx-10).
Immunohistological staining and flow cytometry analysis
CD44
þ cells were searched for by immunochemistry in formol-fixed
tumour histological sections, prepared as described earlier (Marangoni
et al, 2007) and stained with biotin-conjugated anti-CD44 mAb
Hermes-3 (Picker and Butcher, 1992). The frequency of CD44
þ cells
was assessed in tumours by flow cytometry. A single-cell suspension
was prepared from tumours by gentle mechanical crushing, and
filtration through cotton gauzes and enzymatic digestion (0.05%
trypsin/0.025% EDTA). After washing, cells were labelled with FITC-
conjugated P245 anti-CD44 mAb (1mgp e r1 0
5cells) or IgG1 (50-fold
diluted, BD Biosciences, Le Pont-De-Claix, France). The proportion of
CD44
þ cells was measured by flow cytometry relative to isotype-
matched controls, using a FACSvantage (Becton Dickinson, San Jose,
CA, USA). Each measurement was done on 5,000 cells. Dead cells were
excluded using 7-AAD.
RT–PCR analysis
CD44 mRNA expression was analysed by nested RT–PCR
using human specific intron-spanning primers (designed with
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sthe PrimerExpress Software, Applied Biosystems, Courtaboeuf,
France) from mRNA of tumours or fat pad tissues frozen in liquid
nitrogen and extracted as described earlier (Delaunay et al, 2007).
The mRNA levels of proinflammatory human cytokines (IL-1b,
TGFb1, Oncostatin M and TNF-a) were measured by real-time
quantitative RT–PCR, using TaqMan Gene Expression Assays with
Assays-on-Demand (Applied Biosystems), and carried out with
TaqMan universal PCR master mix (Applied Biosystems), and
with an ABI PRISM 7700 Sequence Detection System (Applied
Biosystems). mRNA expression of the human porphobilinogen
deaminase gene was used as an internal standard.
The differences between median DCT values from P245-treated
and control groups were considered as statistically significant for
Pp0.05 (unpaired Student’s t test).
RESULTS
Two different HBCx, originating from aggressive primary
tumours (Marangoni et al, 2007), were used to test the effect of
P245 mAb on tumour growth. CD44 expression was analysed
by both FACS analysis and immunohistochemistry (IHC).
FACS analysis indicated that HBCx-8 and HBCx-3 consisted of
25% and 36% CD44
þ cells (Figure 1A), respectively, with a
heterogeneous staining in both xenografts showed by IHC
(Figure 1B). In HBCx-8 few isolated strongly staining cells
(Figure 1A) were observed in the well-vascularised tumour
periphery with a progressive increase in CD44
þ cells towards
the hypoxic/necrotic central area (Figure 1A). In HBCx-3 a very
strong CD44 staining was found in cancer cell islets near within
the necrotic areas (Figure 1A).
To evaluate the anti-tumoral effects of CD44 targeting in vivo,
the P245 mAb was injected intraperitoneally three times weekly
into nude mice. The tumour growth inhibition (TGI) in the P245
mAb-treated group was 70% at day 28 (Po0.01) in both
xenografts, with HBCx-3 tumour growth being fully stabilized as
early as day 5, whereas HBCx-8 was strongly inhibited from days
15–20 (Figure 1C). After cessation of the antibody treatment
(at day 51), HBCx-8 growth delay was prolonged 2.5-fold
when compared with the control group receiving murine irrelevant
IgG1.
At the end of treatment, tumours were excised and analysed for
proliferation and apoptotic markers and cytokines induction
known to be associated to CD44 receptor ligation by specific
antibodies (Delaunay et al, 2007). Whereas no changes were found
in Ki67 or apoptosis markers (data not shown), P245 mAb
treatment was associated with increased expression of genes
encoding for human IL-1b, TGF-b1, OSM and TNF-a by 43-, 24-,
13- and 8-fold, respectively (Figure 1D).
We next addressed the role of CD44
þ cells in initiating
tumour recurrences after conventional therapy. We took advan-
tage of the triple-negative HBCx-10, which is exquisitely sensitive
to combined adriamycin/cyclophosphamide (AC), a treatment
commonly used for this breast cancer subtype (Rouzier et al,
2005). A single AC injection in mice with a medium tumour
volume of 100mm
3 (usually 75 days after tumour graft) induces a
complete regression of all tumours by day 35, both by local
palpation and histological analysis of the injected fat pads
Figure 2A. At this period of complete remission, human CD44
transcripts are detected by semiquantitative nested RT–PCR, in
the fat pads at the site of the tumour graft (detection threshold
huCD44
þ cells: one in every 10
7cells) (Figure 2B), showing
that at least a fraction of CD44
þ cells were resistant to AC. The
presence of CD44
þ cells during tumour remission is confirmed
by IHC analysis (Figure 2C). Small islets of human tumour
cells strongly stained for CD44 are visible in the mouse tissue fat
pad. In fact, HBCx-10 tumours recurred locally with high
frequency, affecting 16 of 21 mice (76%) after 4–6 weeks of
complete tumour regression (see Figure 2A). To test whether
CD44 targeting could affect tumour relapse, the P245 mAb
was injected during the tumour remission. As shown in
Figure 2A, treatment by the P245 mAb decreased the freq-
uency of tumour recurrence to 31% (31%, Po10
 3), whereas
injections of IgG1 isotype control had no effect. These results
support the idea that CD44
þ surviving cells play a role in tumour
recurrences.
DISCUSSION
Here we show for the first time that CD44 targeting with the
P245 mAb strongly inhibits the growth of HBCx, suggesting that
CD44
þ cells play an important role in tumour growth-driving
mechanisms. This effect was associated with the activation
of cytokine gene expression, suggesting that these cytokines
may be involved in the P245-mediated inhibition of tumour
growth (Pagliacci et al, 1993; Derynck et al, 2001; Shen et al,
2002; Underhill-Day and Heath, 2006). Interestingly, inhibition
of breast cancer stem cells by TGF-b1 was reported recently
(Tang et al, 2007) and TGF-b1 signalling is functional in CD44
þ
breast cancer cells (Derynck et al, 2001). In the treated tumours,
there was no evidence of decreased expression of the cell
proliferation markers such as Ki67 or activation of apoptotic
pathways. Moreover, the fact that tumours regrew on stopping
the treatment suggests that the P245 mAb did not completely
eradicate all malignant cells. In fact, CD44
þ cells still persist in
the treated HBCx-3 at the end of treatment, as shown by IHC,
suggesting that CD44 targeting could have a cytostatic effect. To
improve the therapeutic benefit of CD44 targeting, it might be
necessary either to increase CD44 accessibility, or P245
dosage or length of administration. CD44-targeted therapy of
breast cancer might therefore require a continuous administration
of the P245 mAb, as is the case for other antibody-based
therapies, such as with the anti-HER2 mAb (trastuzumab)
(Hudis, 2007). As HA binds to CD44 receptor, we asked
whether HA could also inhibit the post-chemotherapy recurrence
of breast cancer xenografts. We found that administration of
exogenous HA, at the same dose and the same frequencies
as P245, did not decrease significantly the frequency of
tumour recurrence (Figure 2A). This result is in agree-
ment with the otherwise published results reporting that
HA usually does not inhibit tumour growth. Interestingly,
P245 mAb does not block HA binding to mammary tumour
cells (data not shown), indicating that P245 and HA bind
distinct regions of the CD44 protein. Therefore, it is not
surprising that HA does not recapitulate the TGI provoked by
P245, as it is now well established that the engagement of distinct
regions of CD44, with specific mAbs or with HA, triggers
distinct biological effect (Mu ¨ller-Sieburg et al, 2000; Gadhoum
et al, 2004).
In breast cancer treatment, combined chemotherapy and
radiotherapy can induce disease remission; however, tumour
recurrences are frequent and responsible for treatment failures.
Such recurrences are due to the persistence and proliferation
of chemoresistant breast cancer cells. This is particularly true
for basal-like breast cancers, which are sensitive to anthracyclines
and taxanes combinations, but have higher risk of recurrence
after therapy and worse survival rates (Fadare and Tavassoli,
2008). By using a tumour xenograft originating from a human
basal-like breast cancer, we show that the eradication of the
large bulk of tumour cells by chemotherapy is associated with
the presence of CD44
þ cancer cells, suggesting that a subpopula-
tion of CD44
þ tumour cells survives in spite of the macro-
scopic complete tumour remission induced by chemotherapy.
The fact that P245 treatment during tumour remission inhibits
tumour recurrence suggests that CD44
þ cells play a direct
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srole in the tumour recurrence, providing an interesting
target and a useful model to finalise breast cancer therapies
associations.
In conclusion, we show here for the first time that targeting
CD44
þ breast cancer cells inhibits tumour growth and post-
chemotherapy tumour recurrence in both ERþ and basal-like
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Figure 1 CD44 expression in human breast cancer xenografts (HBCx) and effects of P245 anti-human CD44 mAb on HBCx growth. (A) Flow cytometry
assay of CD44
þ cells in HBCx-8 and HBCx-3 xenografts. (B) Immunohistology of HBCx stained with biotin-conjugated Hermes-3 anti-human specific CD44
antibody. Haematoxylin/Eosin sections  200. Upper: Untreated HBCx-8; a single strongly positive CD44
þ cancer cell (arrow) isolated among CD44
  cancer
cells (left): membrane staining is seen, with a heterogeneous pattern. Untreated HBCx-8 tumour; a gradient of staining is observed from the peripheryt ot h e
central areas (right). Untreated HBCx-3 tumour; strong staining of surviving clumps of cells (arrows), within necrotic areas in the centre of the tumour. Middle:
Untreated HBCx-3 showing low staining of CD44
þ cells in the periphery of the tumour. Bottom: HBCx-3 after treatment showing residual CD44
þ cells. (C)
Anti-tumoural effects of P245 mAb on tumour growth. Growth curves; relative tumour volume (RTV) of HBCx-8 (upper) and HBCx-3 (bottom) as a function of
time (days after start of treatment), IgG1 isotype control (black squares) or P245-treated (white squares) with P245 mAb. Mice bearing HBCx-3 and HBCx-8
tumours, at a mean volume of 100mm
3, were randomized into treatment and control groups (8 to 12 mice per group). The P245 mAb was injected
intraperitoneally (i.p.) at a dose of 3mgkg
 1 in 100ml of 0.9% NaCl, thrice weekly for 4 to 8 weeks. The control group was not treated or received IgG1injections
(the same dose and protocol as for P245 mAb). The RTV for each mouse was the ratio of tumour volume at time t to the initial volume. Mean RTV and standard
errors were calculated. Mice were ethically killed when the tumour volume reached 2500mm
3. Statistical significance of observed differences was calculated by
the paired Student0s t test by comparing the RTV in the treated (T)a n dc o n t r o l( C) groups for the tumour growth curves and by the w
2 test for the tumour
relapse frequencies. (D) Embedded gene expression changes induced by anti-CD44 mAb treatment of HBCx-8: mRNA levels of proinflammatory human
cytokines (IL-1b,T G F b1, Oncostatin M and TNF-7a) were measured by real-time quantitative RT–PCR. mRNA was extracted from frozen tumours excised at
the end of P245 treatment. Shown are results from one representative of three experiments. Each sample was run in duplicate and the mean value was expressed
as cycle threshold (CT), *p0.05, **p0.02, ***p0.05.
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Figure 2 HBCx-10 recurrences after adriamycin/cyclophosphamide (AC) chemotherapy and their prevention by P245 mAb treatment. Detection of
human CD44 transcripts in the post-chemotherapy tumour residue. (A) Tumour growth curves of HBCx-10 after chemotherapy alone or chemotherapy
followed by P245 anti-CD44 mAb treatment. Tumour bearing mice were all treated with the AC combination (adriamycin 2mgkg
 1, cyclophosphamide
100mgkg
 1) when the tumour reached a median volume of 100mm
3. Mice were then separated into two groups until tumour remission was complete
(i.e., the tumours were not palpable). The y axis shows the tumour volume median. One group was treated three times per week with P245 anti-CD44
mAb (3mgkg
 1 for 5 weeks). The control group was untreated. (B) Detection of human CD44 transcripts in the residual fat pad tissue during the post-
chemotherapy remission. CD44 mRNA expression was analysed by nested RT–PCR using human specific intron-spanning primers (designed with the
PrimerExpress Software, Applied Biosystems) from mRNA of tumours or fat pad tissues frozen in liquid nitrogen and extracted as described earlier. Cross-
species amplification and detection threshold of human CD44-transcribing cells was determined with a concentration range of human breast cancer cells
(MDA-MB231) in murine fibroblasts (NIH-3T3). Data are shown as the human CD44 signal obtained after two amplification sets of 2mg of cDNA from
HBCx-10 tumours before adriamycin/cyclophosphamide (AC) treatment (mice no.1 and 2), during the relapse in the control group (mice no. 6, 7 and 8)
compared with mice fat pad during complete remission (mice no. 3, 4 and 5). Shown are results from one representative of three experiments. (C)
Immunohistology of HBCx-10 tumour nodules during tumour remission stained with biotin-conjugated Hermes-3 anti-human specific CD44 antibody.
Haematoxylin/Eosin sections  400 (left) and  200 (right). Left: single tumour cell nodules strongly positive for CD44 (arrow) isolated among unstained
small murine cells. Right: murine tissue containing adipocytes and stroma with disseminated clumps of human tumour cells expressing CD44 (arrows).
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associated with induction of cytokines known to have anti-
proliferative activity. The finding that CD44
þ cells play a key role
in chemoresistant breast cancer recurrences provides an innova-
tive strategy to improve breast cancer treatment.
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